Around four fifths of what the country consumes is manufactured inside it, by more plants than before the war, and it exports to more than twenty other markets. So the first question is not who would carry your product but whether a gap exists for it. What follows is how the market actually works, what a credible partner here has to hold, and what we would establish before anyone was appointed.
Demand divides three ways, and the money behind each behaves differently. Government tenders sustain much of the domestic manufacturing base. Retail pharmacy sits on household spending in a country where the great majority of people are below the poverty line and pharmacists report selling on credit. And humanitarian procurement, run by UN agencies and the larger NGOs, is a third channel with its own rules, its own prequalification and no Syrian agent in the middle of it.
That third channel is also the one under the most pressure. The health sector response recorded close to thirteen million people needing assistance in mid 2026 against a funding appeal less than a fifth met, and in late 2025 the World Health Organization reported that shortfalls had forced several hundred facilities to stop or cut back services. For a brand owner the consequence is awkward but worth facing early: the buyer with the clearest procedures and the fewest counterparty problems is also the buyer with the least reliable money.
Before 2011 roughly nine tenths of medicines consumed in Syria were made there, across some seventy factories. The industry did not collapse. By 2026 the health ministry put domestic supply at over eighty per cent of demand, and the sector was exporting more than a thousand products to twenty-three countries. Counts of operating plants differ between credible sources, so we do not quote one, but both point the same way: there are more now than before the conflict. A generics brand arriving here is not filling a gap, it is joining a crowded domestic field under price control.
Which leaves a real but narrow opening, and one that is being closed deliberately. What is imported is specialty, biological and immunological product that local plants do not make — and the ministry runs a localisation programme under which an investor wanting to produce conventional medicines must first operate a specialty line. Meanwhile the regulator itself is mid-rebuild: medicines and devices are overseen directly by ministry directorates, with a separate authority modelled on Jordan’s being set up through 2026 and still unfunded as of that June. The rules a partner works to today are not the rules that will apply.
The centre of gravity in Syrian pharmaceuticals is manufacturing, not distribution. The industry supplies most of the domestic market, has more plants running than it did before the conflict, and exports over a thousand products. Several of the larger manufacturers also hold agencies for foreign brands, so the company you are considering as a route to market may also be competing with you from its own production line. That is not a reason to rule anyone out. It is a reason to ask what else they make before you discuss terms.
Beneath that, public information thins out quickly. The most specific published list of distribution agents we could find dates from 2020, which in this market is several structural changes ago, and we do not repeat it. Trade statistics are no better: the most recent pharmaceutical import figure in the main international series is from 2010. Anyone quoting you a current market size or a league table of importers is either working from something they have not shown you or estimating and not saying so.
What can be established is narrower and more useful. Company records sit with the Commercial Registry, and while the portal is not usable from abroad, extracts can be obtained in country through counsel. An online incorporation platform launched in mid 2026 and registrations have been running at a healthy rate, so the population of companies is growing and changing. Verification here is a physical process, done locally, not a database lookup.
For imported medical supplies the health ministry publishes a registration pack, and reading it is the fastest way to understand what your counterparty is actually responsible for. It is also, in effect, a free due diligence checklist: the ministry is vetting the agent alongside the product, so everything it demands is something you should hold a copy of.
This market rewards slow diligence and punishes the usual shortcuts, because the things you would normally check from a desk cannot be checked from one. These are the questions we would want answered, in this order.
Specialty, biological and immunological products are what the country imports. If local plants can make something close to your product, you are entering a price-controlled market against an established incumbent.
The ministry has been requiring investors who want to produce conventional medicines to open a specialty line first. The gap you are entering is being closed deliberately, so the question is how long it stays open.
Prescription and most over-the-counter prices are set centrally. Model the price you will be given rather than the one you would like, and check what it does to the margin left for a distributor.
That means a commercial register extract obtained in country through counsel, with ownership and signing authority visible on it, rather than a scan supplied by the candidate.
Reports of faster settlement through commercial banks are encouraging but rest on thin sourcing. Test one real payment end to end before you contract, rather than assuming the published picture applies to you.
The ministry has itself identified a gap in the national cold chain, and the functioning examples are largely aid-funded and solar-backed. If your product needs temperature control, audit the chain physically, end to end.
A new medicines authority has been in preparation with Jordanian technical support and was still waiting on funding in mid 2026. Keep the term short and the exit written, because the rules the agreement assumes are being rewritten.
The most common error is reading the damage figures and inferring an open field. Domestic manufacturing did not collapse; it grew. A generics brand arriving with a standard portfolio is competing with an incumbent industry that is already exporting.
Appointments written for five or more years are being made against a regulator that is in the middle of being replaced, and against registration rules expected to move with it.
It has the clearest procedures of the three buyers and the least dependable funding. Treat it as a route worth pricing, not as the reason to enter.
Ownership, licences and capability cannot be confirmed remotely here. Budget for someone to go, or accept that you are appointing on trust.
For imported medical supplies the health ministry’s registration pack requires an authenticated authorisation from the manufacturer to a named local agent, along with that agent’s own commercial register and a profile of its technical staff. So in practice the route runs through a local party. We could not establish from published sources whether the same requirement applies to medicines as distinct from devices, and we would rather say so than assume it.
The Ministry of Health, directly, through its pharmaceutical directorates. There is no separate agency of the kind Saudi Arabia and the UAE have. One is being created with Jordanian technical support, and as of mid 2026 it was still waiting on funding, so anyone planning around it should check its status rather than assume it exists.
Rarely. Domestic manufacturers supply the large majority of the market, operate more plants than before the conflict, and export more than a thousand products to twenty-three countries. The imported niche is specialty, biological and immunological product that local plants do not make, and government policy is actively trying to bring even that onshore.
Partly, and not from abroad. The commercial registry is not usable as a public search from outside the country, so extracts are obtained in person or through counsel in Damascus or Aleppo. Whether ownership and beneficial ownership appear on those extracts is not something we could confirm, so plan on physical verification rather than a database check.
No. The ministry sets prices for prescription medicines and most over-the-counter products, and in April 2026 confirmed it had agreed not to raise them. Build the commercial case on the controlled price, and work out what margin that leaves for whoever distributes the product.
Sometimes. UN agencies and the larger NGOs buy against their own international prequalification rather than through a Syrian appointment. That reaches different patients from the retail and hospital channels and the funding is unreliable, but it is a genuine route and worth pricing against the cost of appointing a distributor.
A market that makes most of its own medicines needs a different conversation from one that imports them, and generic advice about market entry does not survive contact with it. Tell us what you are considering and we will say plainly what we think is possible and what is not.
How we verify How a distributor search runs